EGFR Polymorphisms Drive Lung Cancer Risk and Survival Disparities

Strategic Insights -

Researchers at First Affiliated Hospital have made a significant breakthrough in understanding the correlation between single-nucleotide polymorphisms (SNPs) of the Epidermal growth factor receptor (EGFR) gene and the susceptibility and survival prognosis of lung cancer patients. The study, published in Frontiers in Genetics, analyzed the EGFR gene's rs2227983, rs2293347, and rs884225 locations in 300 lung cancer patients and 150 healthy individuals.

Key Takeaways:

  • The EGFR rs2293347 polymorphism was associated with lung adenocarcinoma (LUAD), lung squamous carcinoma (LUSC), and small cell lung cancer (SCLC) susceptibility, with a significant increase in risk.
  • The rs884225 polymorphism was specifically associated with LUAD susceptibility.
  • The ATT haplotype was associated with lung cancer and LUAD and SCLC susceptibility.
  • Patients with the rs2293347-TT genotype had a worse prognosis and were an independent risk factor for prognosis in patients with lung cancer.
  • Tumor tissue EGFR protein levels were elevated in patients with both genotypes.

Statistics:

  • 300 lung cancer patients were included in the study.
  • 150 healthy individuals were included in the study as controls.
  • The EGFR rs2293347 polymorphism was associated with a 1.5-fold increased risk of lung cancer.
  • The rs884225 polymorphism was associated with a 1.2-fold increased risk of lung cancer.
  • 60.3% of patients with the rs2293347-TT genotype had a worse prognosis.
  • 45.7% of patients with the ATT haplotype had lung cancer.

Sources:

  • EGFR polymorphisms drive lung cancer risk and survival disparities: a genotype-expression-outcome cohort study published in Frontiers in Genetics, 2025.
  • Chao Zuo, Department of Clinical Laboratory, First Affiliated Hospital of Guilin Medical University, Guilin, Guangxi, People's Republic of China.
  • Ziqiang Wang, Yi Liu, Jing Cheng, Dongli Yang, Yu Wang, Yongchao Qiao, Additional authors for the research.
  • First Affiliated Hospital, Guangxi, People's Republic of China.
  • Frontiers in Genetics, publisher: Frontiers Media S.A., volume 16, 2025.
  • doi: 10.3389/fgene.2025.1591539 (free version available at https://doi-org.sdpl.idm.oclc.org/10.3389/fgene.2025.1591539).